Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

Shares of Cellectis S.A. (NASDAQ:CLLS) tanked on Tuesday after Allogene Therapeutics Inc. (NASDAQ:ALLO) cited a favorable arbitration outcome for partner Servier in its dispute with Cellectis related to the CAR-T therapy cemacabtagene ansegedleucel (cema-cel). The win reconfirmed Allogene’s full development and commercial control of cema-cel in the U.S., the EU and the U.K., while clearing the path to obtain full global commercialization rights from Servier. Also Read: Why Cellectis Stock Is Trading Higher Today The tribunal: Rejected Cellectis’s allegations relating to alleged breaches by Servier of its development obligations. Rejected Cellectis’s financial claims, finding that milestone payments tied to the pivotal trial are not due until U.S. Food and Drug Administration acceptance of a Biologics License Application. Ordered only a partial termination of the license, strictly limited to the UCART19 V1 product (formerly known as ALLO-501, which was discontinued in 2021 in favor of ALLO-501A/cema-cel) and directed Cellectis to negotiate a direct license to Allogene on terms substantially similar to the existing agreement, if Allogene elects to pursue it. With this legal matter resolved, Allogene enters 2026 with improved fundamentals. The company is approaching one of the most meaningful catalyst periods in the allogeneic CAR T field, including a first-half 2026 interim futility analysis comparing MRD conversion with cema-cel following standard fludarabine/cyclophosphamide (FC) lymphodepletion versus observation in first-line patients with large B-cell lymphoma (LBCL). Price Action: CLLS stock is down 17.35% at $3.96, and ALLO stock is up 1.37% at $1.49 at the last check on Tuesday. Read Next: Tesla Rival Xpeng Receives Level 3 Autonomous Testing Permit Amid Planned Robotaxi Push: Report Image: Shutterstock